DermiSense, Inc. Company Profile

Background

Overview

DermiSense, Inc., founded in 2018 and headquartered in Cary, North Carolina, is a medical technology company specializing in the development of innovative diagnostic solutions. The company's mission is to provide easy and accessible diagnostic testing through minimally invasive dermal interstitial fluid (ISF) collection, eliminating the need for painful blood draws. By focusing on non-invasive methods, DermiSense aims to make diagnostics quick, affordable, and pain-free, benefiting individuals in remote areas and those with a fear of needles, while also reducing healthcare costs.

Mission and Vision

DermiSense envisions a future where diagnostic testing is accessible, efficient, and minimally invasive. The company is committed to transforming the diagnostic landscape by offering solutions that simplify the testing process and improve patient comfort.

Primary Area of Focus

The company's primary focus is on developing a flexible, bio-inert organic composite microneedle platform designed to extract dermal interstitial fluid for local analysis or rapid lab tests. This technology aims to replace traditional blood sampling methods, providing a less invasive and more patient-friendly alternative.

Industry Significance

DermiSense's innovative approach addresses significant challenges in the medical diagnostics industry, particularly the discomfort and invasiveness associated with blood draws. By offering a painless and efficient method for biomarker analysis, the company has the potential to revolutionize diagnostic testing, making it more accessible and less resource-intensive.

Key Strategic Focus

Core Objectives

• Innovation in Diagnostics: Develop and commercialize minimally invasive diagnostic tools that simplify the testing process and enhance patient comfort.

• Market Expansion: Establish partnerships with healthcare providers, research institutions, and government agencies to integrate DermiSense's technology into various diagnostic applications.

• Regulatory Advancement: Achieve necessary regulatory approvals, including FDA clearance, to bring products to market and ensure compliance with industry standards.

Specific Areas of Specialization

DermiSense specializes in the extraction and analysis of dermal interstitial fluid, focusing on the development of microneedle-based platforms that enable painless and efficient biomarker collection. This specialization allows for the monitoring of various biomarkers, including proteins, cytokines, and lymph, without the need for traditional blood draws.

Key Technologies Utilized

• Microneedle Technology: Utilizing sub-millimeter microstructured needles to extract dermal interstitial fluid painlessly and efficiently.

• Bio-Inert Organic Composite Materials: Employing materials that are biocompatible and flexible, ensuring comfort and safety during use.

• Zero-Power Extraction Method: Implementing a passive extraction process that does not require external power sources, enhancing the device's usability and convenience.

Primary Markets or Conditions Targeted

DermiSense's technology is applicable across various markets, including:

• Clinical Diagnostics: Providing a less invasive alternative for routine biomarker testing in healthcare settings.

• Athletic Performance Monitoring: Enabling athletes to monitor physiological parameters for optimized training and recovery.

• Trauma Care: Allowing for continuous monitoring of critical patients to assess physiological compensation and detect early signs of infection.

Financials and Funding

Funding History

As of the latest available information, DermiSense has raised a total of $2.7 million in seed funding. This capital is intended to support the completion of multi-site human studies, scale manufacturing capabilities, and achieve quality system certification.

Recent Funding Rounds

The seed funding round was completed in 2025, with the raised capital allocated towards:

• Clinical Trials: Conducting multi-site human studies to build a robust data package for FDA submission.

• Manufacturing Scale-Up: Finalizing design for manufacturing, establishing a pilot production line, and achieving quality system certification.

• Team Expansion and Partnerships: Hiring key roles in engineering, research, clinical, and regulatory affairs, and engaging expert partners in design, regulatory affairs, and legal.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Intended Utilization of Capital

The funds are primarily allocated to advance clinical validation, scale manufacturing processes, and prepare for regulatory submissions, positioning DermiSense for full market launch and broader adoption of its diagnostic solutions.

Pipeline Development

Key Pipeline Candidates

DermiSense is focusing on the development of its microneedle-based platform for the extraction and analysis of dermal interstitial fluid. The technology is currently at Technology Readiness Level (TRL) 4.5, with ongoing efforts to advance through proof-of-concept, preliminary human studies, and active pilot testing.

Stages of Clinical Trials or Product Development

• Year 1 (2026): Complete initial human validation and multi-site clinical trials with partners. Finalize Design for Manufacturing (DFM) and engage FDA via pre-submission.

• Year 2 (2027): Scale to 1,000 pilot units, achieve ISO 13485 certification, and prepare formal FDA filing. Enable initial sales to strategic diagnostic partners and research teams.

• Long-Term: Expand clinical trials, integrate additional diagnostic tests, and launch commercially with broader market adoption.

Target Conditions

The technology is designed to monitor various biomarkers, including proteins, cytokines, and lymph, to investigate physiology, pharmacokinetics, and immune response.

Relevant Timelines for Anticipated Milestones

• 2026: Completion of initial human validation and multi-site clinical trials.

• 2027: